INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.
Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
Primary objectives
- Assess the response rate in patients with recurrent or refractory B-cell NHL or Hodgkins
disease, treated with the combination of the gemcitabine and irinotecan.
Secondary objectives
- Assess progression free survival in these patients treated with this regimen.
- Assess toxicity of this regimen in this group of patients.